SAN FRANCISCO, May 24, 2017 /PRNewswire/ -- ShangPharma Innovation (SPI) today announced the appointment of Mohamad Moghadam-Tabrizi to the position of Senior Vice President, Business Development.
Mr. Tabrizi previously served in senior and executive level positions in corporate business development at Nektar, investor relations and corporate communications at
"We are very pleased to welcome Mohamad to ShangPharma Innovation. He is a highly successful professional with broad transaction expertise in all aspects of business and corporate development in the biopharmaceutical industry — financial, investor, licensing, strategic, and more," said Walter H. Moos, CEO of SPI.
Earlier in his career, Mohamad was a researcher at the Howard Hughes Medical Institute, Stanford University Medical School, and Systemix. He received his undergraduate and graduate training in genetics and biological sciences at the University of California Davis and Stanford University and an MBA from Cornell University.
Mohamad will aid in the achievement of key objectives at SPI which include facilitating and accelerating drug discovery with a focus on therapeutics and platform technologies, and also offering funding, other support, and incubator space to entrepreneurial partners. These partnerships include proof-of-concept research at academic and major medical centers, research institutes, and early-stage start-ups with the goal of achieving industry collaborations and/or venture capital financing.
FOR MORE INFORMATION
ShangPharma Innovation, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shangpharma-innovation-appoints-mohamad-moghadam-tabrizi-as-senior-vice-president-of-business-development-300462926.html
SOURCE ShangPharma Corporation
Subscribe to our Free Newsletters!